J&J's Janssen and PATH Partner to Develop Rilpivirine Formulation - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

J&J's Janssen and PATH Partner to Develop Rilpivirine Formulation



PATH, an international nonprofit organization, has entered into a licensing agreement with Janssen R&D Ireland to develop an injectable form of the HIV medicine rilpivirine, part of Johnson and Johnson.

The agreement allows PATH and its partners, Janssen, the HIV Prevention Trials Network, and the Division of AIDS at the National Institutes of Health, to advance the product to Phase II multisite safety studies in the US and Africa, with trials expected to begin in 2014. The trials will build on the results of ongoing Phase I work to establish the viability of the drug candidate.

An injectable formulation of rilpivirine could become a new pre-exposure prophylaxis (PrEP) intervention against HIV type 1. PrEP is a prevention strategy that involves the use of antiretroviral medications to reduce the risk of HIV infection in healthy uninfected people at risk for acquiring the virus.

Rilpivirine is a highly potent, non-nucleoside reverse transcriptase inhibitor of HIV-1, currently commercialized by Janssen as an oral, once-daily treatment for adults who have not been treated previously with antiretroviral therapy. It is used in combination with other antiretroviral therapies

Source: PATH

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here